Outsourced Pharma Compliance and Shared Services for the UK and Europe
Your compliance function, run with you.
Our outsourced pharma compliance team works within your SOPs and systems to review materials, support HCP engagements and manage transparency reporting, including EFPIA disclosure processes. Shared services, GBS and GCC support adds operational capacity while you retain accountability and oversight.
Discuss this service
The challenge
Add capacity when compliance work outgrows the team
Rising review volumes and new-market activity can put pressure on a lean compliance function. Backlogs, repeated review cycles and inconsistent records take time away from oversight. We provide operational support through agreed processes so your team can manage workload while retaining accountability.
Who this service is for
For emerging biotechs building their operating model, pharmaceutical teams with limited review capacity and established organisations developing shared services, GBS or GCC functions. An engagement can start with one activity or market and expand as requirements change.
How delivery works
We agree the activities, review responsibilities, service measures and escalation routes, then work within your SOPs and systems. Scope can include promotional and medical materials, HCP engagements, FMV assessment, transparency reporting and associated records. Reporting makes volumes, turnaround, exceptions and recurring issues visible to your team.
What we can take on
Shared Services / GBS / GCC: scope of support
Activity, event and congress review
HCP engagement and fair market value assessment
Transparency reporting and disclosure
Operational compliance support across markets
Centralised workflow and evidence management
What this gives you
Dependable capacity without building a full in-house team
Consistent decisions, records and turnaround times
A service that can scale by market, activity or workload
Why Eunomia
Expertise connected to delivery
Specialist review capability is supported by workflow management and operational coordination. We connect local expertise when the agreed scope requires it and use regular governance to review performance. Your organisation retains oversight and the decision rights defined for the engagement.
Meet your compliance specialists →Service case study
Materials-review turnaround reduced from five days to two
A UK pharmaceutical company expanding across Europe received a structured review service with experienced reviewers, workflows, SOPs and reporting. The published case study reports review cycles falling from four to two. These results relate to that engagement and are not a promised outcome for every client.
Read the case study →How an engagement runs
From scope to working process
- 01
Agree the service
Define the activities, volumes, review responsibilities, service measures and escalation routes.
- 02
Onboard
Align with your SOPs, systems, templates and approval rights before reviews begin.
- 03
Deliver
Carry out the agreed reviews, assessments and reporting within your processes.
- 04
Review performance
Report volumes, turnaround, exceptions and recurring issues through regular governance.
The rules behind this service
Frameworks we work to
Shared-service reviewers work to the same rules as your in-house team. These are the frameworks most often behind materials review, HCP engagement and disclosure work.
Start here
MHRA Blue Guide
The MHRA’s guidance on how it applies the UK legal requirements for advertising medicines in Part 14 of the Human Medicines Regulations 2012.
Official source: MHRA Blue Guide2024 ABPI Code of Practice
Took effect on 1 October 2024, with a transition period to 31 December 2024, and is administered by the PMCPA independently of the ABPI. Clause 24 addresses contracted services, including legitimate need, selection, advance contracting and remuneration reflecting fair market value.
Official source: PMCPA: 2024 ABPI CodeEFPIA Code of Practice
Sets European standards for interactions with healthcare professionals, healthcare organisations and patient organisations, including annual disclosure of transfers of value within six months of the end of each calendar year. Member associations transpose it into national codes and may adopt stricter standards.
Official source: EFPIA CodeDisclosure UK
The ABPI’s public database of industry payments to UK healthcare professionals and organisations, part of a Europe-wide transparency initiative.
Official source: Disclosure UKInformational summary, not legal advice. Sources checked September 2026.
Questions, answered
Shared Services / GBS / GCC FAQs
What is a healthcare compliance shared service?
A dedicated team performs defined compliance activities through agreed processes, systems, service levels and escalation routes while your organisation retains oversight and accountability.
Can the service work within our existing SOPs and systems?
Yes. The operating model is designed around your approved procedures, technology, decision rights and documentation requirements.
Which activities can be included?
Typical scope includes materials and activity review, events and HCP engagements, fair market value, disclosures, transparency reporting and associated records.
Can we start with one process or market?
Yes. A shared service can begin with a defined activity, team or market and expand after the workflow and service levels are proven.
Who remains accountable for compliance decisions?
Your organisation retains ultimate accountability. Roles, delegated authority, review routes and escalations are defined clearly at the outset.
How is performance managed?
The service can use agreed measures for volume, turnaround, quality, exceptions, escalation and stakeholder experience, supported by regular governance reviews.
Which pharma companies are known for transparency?
There is no single cross-market ranking that identifies the pharmaceutical companies that are “most transparent.” Check the relevant public disclosure sources for each country, compare the same reporting year and categories, and review each company’s methodology and correction process. Public disclosures are useful evidence about reported relationships, but are not a complete measure of a company’s overall ethics or compliance effectiveness.
Tell us what is on your desk.
We will listen, ask a few questions and recommend the right scope—without obligation or pressure.
Start a conversation